Does Vraylar Cause Nightmares?
Nightmares are not listed as a recognized side effect of Vraylar (cariprazine) in the FDA-approved prescribing information, though the drug does cause "trouble sleeping" as a common side effect. 1
Understanding the Evidence
The FDA drug label for Vraylar explicitly lists the most common side effects, which include difficulty moving, tremors, restlessness, sleepiness, nausea, vomiting, indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness 1. Notably absent from this comprehensive list is any mention of nightmares or abnormal dreams.
Mechanistic Considerations
From a pharmacological perspective, cariprazine's mechanism makes nightmares theoretically possible but not particularly likely:
Dopamine modulation: Cariprazine is a dopamine D3-preferring D2/D3 receptor partial agonist. According to nightmare disorder guidelines, drugs affecting dopamine can produce nightmares 2. However, research evidence shows cariprazine actually suppresses REM sleep in animal models 3, which would theoretically reduce rather than increase nightmare frequency, since nightmares typically occur during REM sleep.
REM sleep effects: The REM-suppressing properties of cariprazine 3 are similar to other antidepressants that reduce nightmares rather than cause them. This mechanism may actually contribute to cariprazine's effectiveness in treating depressive symptoms.
Clinical Safety Data
Multiple real-world and clinical trial analyses of cariprazine have not identified nightmares as a safety signal:
- A 2025 pooled safety analysis of phase 2b/3 trials specifically evaluated adverse events, with only akathisia, nausea, and insomnia occurring in ≥5% of patients at twice the rate of placebo 4
- Comprehensive reviews of cariprazine's safety profile across schizophrenia and bipolar disorder consistently mention extrapyramidal symptoms, akathisia, nausea, and constipation as primary concerns—not nightmares 5, 6
- Real-world data analyses have focused on metabolic and cardiovascular effects, not sleep disturbances beyond general insomnia 7
Clinical Interpretation
If a patient on Vraylar reports nightmares, consider these alternative explanations:
Underlying psychiatric condition: Nightmares are associated with schizophrenia-spectrum disorders, depression, anxiety, and bipolar disorder—the very conditions Vraylar treats 2
Concomitant medications: Review other medications affecting norepinephrine, serotonin, or dopamine that are known nightmare triggers 2, 8
General sleep disruption: The documented "trouble sleeping" side effect may manifest as fragmented sleep that increases dream recall or disturbing dreams
Withdrawal from prior medications: If transitioning from REM-suppressing agents, rebound REM sleep can cause increased dreaming 2
Common Pitfall
Do not automatically attribute nightmares to Vraylar without considering the patient's underlying psychiatric diagnosis, which itself carries high risk for nightmare disorder. Up to 80% of PTSD patients experience nightmares, and nightmare disorder affects 4% of the general adult population 2.
Bottom line: While theoretically possible through dopamine modulation, nightmares are not an established or commonly reported side effect of Vraylar based on FDA labeling and extensive clinical trial data. The drug's REM-suppressing properties may actually reduce nightmare frequency. If nightmares occur, investigate other causes before attributing them to cariprazine.